Cabaletta Bio Inc. (CABA) A Top Penny Stock Eyeing Rese-Cel Commercial Launch for Autoimmune Diseases
Key takeaways
- (CABA) A Top Penny Stock Eyeing Rese-Cel Commercial Launch for Autoimmune Diseases Neha Gupta Mon, June 8, 2026 at 12:58 AM GMT+7 2 min read CABA Cabaletta Bio Inc.
- It also presented manufacturing and translational data from the first two autoimmune patients treated with rese-cel treated using Cellares Cell Shuttle platform.
- Consequently, PC-free rese-cel has the potential to enhance access for patients in CAR T centers.
Cabaletta Bio Inc. (CABA) A Top Penny Stock Eyeing Rese-Cel Commercial Launch for Autoimmune Diseases Neha Gupta Mon, June 8, 2026 at 12:58 AM GMT+7 2 min read CABA Cabaletta Bio Inc. (NASDAQ:CABA) is one of the top penny stocks to buy in investors’ stock portfolio. On May 14, Cabaletta Bio Inc. (NASDAQ:CABA) delivered positive clinical and translational data from the first four patients in the lowest dose cohort evaluating preconditioning-free (PC-free) rese-cel, an investigational, autologous CAR T cell therapy for the treatment of autoimmune diseases.
It also presented manufacturing and translational data from the first two autoimmune patients treated with rese-cel treated using Cellares Cell Shuttle platform. It became clear that a higher rese-cel dose would be required in the absence of preconditioning. In addition, 50% of the patients demonstrated compelling, drug-free responses for six months.
Consequently, PC-free rese-cel has the potential to enhance access for patients in CAR T centers. The company has already signed a long-term commercial supply agreement that will ensure rese-cel is produced for thousands of patients at the lowest cost of goods, with minimal capital investment.